Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade

Inclusion Criteria9

• Age ≥ 18 years, no gender limit;
• Pathologically or cytologically confirmed malignant solid tumors;
• Scheduled to receive cisplatin-based chemotherapy combined with PD-1 blockade；
• TPS > 1 %(PD-1);
• Adequate hematological function (leucocyte count ≥ 4000/μL \[to convert to ×109/L,multiply by 0.001\], hemoglobin ≥ 9.00 g/dL \[to convert to grams per liter, multiply by 10\], and platelet count ≥ 100 × 103/μL \[to convert to ×109/L, multiply by 1\]);
• Hepatic function (alanine aminotransferase and aspartate aminotransferase ≤ 2.0 times the upper limit of the reference ranges), and renal function (creatinine clearance ≥ 60 mL/min/1.73 m2 \[to convert to millimeters per second per meter-squared, multiply by 0.0167\])；
• Estimated survival time > 6 months；
• ECOG 0-1 points；
• Participants being informed and signed written consents.